(S048) Identification of Excellent and Poor Prognostic Groups After Stereotactic Radiosurgery for Spinal Metastasis: Secondary Analyses of Mature Prospective Trials

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

We present a survival prediction model that has identified patient subgroups with poor (Group 4) to excellent (Group 1) prognoses. In addition, pretreatment symptoms were predictive of survival and correlated with the prediction of the model. If validated, we believe that this model, possibly in conjunction with patient symptoms, may aid in determining optimal treatment strategies.

Chad Tang, Kenneth Hess, Andrew Bishop, Hubert Pan, Eva Christiansen, Nizar Tannir, Behrang Amini, Claudio Tatsui, Lawrence Rhines, Paul Brown, Amol Ghia; UT MD Anderson Cancer Center

BACKGROUND/PURPOSE: There is uncertainty in the prognosis of patients following treatment of spinal metastases. To stratify patients between poor and excellent predicted survival after stereotactic spine radiosurgery (SSRS), we created a Cox proportional hazards regression model.

PATIENTS AND METHODS: Patients who were enrolled (between 2002 and 2011) in two prospective trials investigating SSRS for spinal metastasis were analyzed. To ensure mature survival data, living patients with < 3 years of follow-up were excluded. A multivariate Cox regression model was utilized to create a survival model via backward selection at P < .05. Pretreatment variables included race, sex, age, performance status, tumor histology, extent of vertebrae involvement, prior therapy at SSRS site, disease burden, and timing of diagnosis and treatment. Four prognostic groups were generated based on the model-derived prognostic index (PI).

To assess whether pretreatment symptoms were associated with survival and survival model predictions, patients were prospectively queried for their pretreatment symptoms via the MD Anderson Symptom Inventory (MDASI) and Brief Pain Index (BPI).

RESULTS: A total of 206 patients were included in this analysis. Median follow-up time was 70 months (range: 37–133 mo) among all living patients (n = 40). Seven variables were selected in the prediction model: female sex (hazard ratio [HR] = 0.7; P = .04), Karnofsky performance status (KPS) (HR = 0.7 per 10% increase; P = .005), prior surgery at the SSRS site (HR = 0.6; P = .005), prior radiation at the SSRS site (HR = 1.7; P = .003), SSRS site as the only site of disease (HR = 0.5; P < .001), number of organ systems involved (HR = 1.4 per involved system; P < .001), and time between initial diagnosis and spine metastasis after variable normalization (HR = 0.6 per log10[time in months+5]; HR = 0.01). The c-index of the stratified and unstratified model was 0.68 and 0.70, respectively.

The median survival time among all patients included in the analysis was 25.5 months and was significantly different among prognostic groups (Group 1 [excellent prognosis]: not reached, Group 2: 32.6 mo, Group 3: 19.7 mo, Group 4 [poor prognosis]: 8.2 mo; P < .001). Patients within the excellent prognosis group exhibited a Kaplan-Meier estimated 10-year survival rate of 71%. Furthermore, all pretreatment symptom metrics were predictive of overall survival and correlated with the model-derived PI (all P ≤ .01).

CONCLUSIONS: We present a survival prediction model that has identified patient subgroups with poor (Group 4) to excellent (Group 1) prognoses. In addition, pretreatment symptoms were predictive of survival and correlated with the prediction of the model. If validated, we believe that this model, possibly in conjunction with patient symptoms, may aid in determining optimal treatment strategies.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content